Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of November 21, 2024 • 10:31 PM ET

Date/Time Source News Release
11/14/2024 09:00 AM EST GlobeNewswire ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
10/22/2024 08:45 AM EDT GlobeNewswire ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
08/15/2024 07:30 AM EDT GlobeNewswire ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
04/17/2024 09:00 AM EDT GlobeNewswire ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
04/10/2024 08:30 AM EDT GlobeNewswire ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
03/26/2024 08:30 AM EDT GlobeNewswire ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
03/21/2024 08:30 AM EDT GlobeNewswire AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
02/27/2024 08:30 AM EST GlobeNewswire ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
02/15/2024 08:30 AM EST GlobeNewswire ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
02/12/2024 08:30 AM EST GlobeNewswire ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
Page

Additional News

As of November 21, 2024 • 10:31 PM ET

Date/Time Source News Release
11/16/2024 04:30 AM EST US Earnings Reports Expected earnings - ABVC BioPharma Inc.
11/14/2024 02:11 PM EST SeekingAlpha ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M
10/22/2024 09:09 AM EDT SeekingAlpha ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb
08/16/2024 09:07 AM EDT SeekingAlpha ABVC BioPharma GAAP EPS of -$0.09
08/12/2024 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, August 12th, 2024
08/12/2024 05:31 AM EDT US Earnings Reports Expected earnings - ABVC BioPharma Inc.
07/18/2024 10:31 AM EDT News Direct ABVC BioPharma's CEO Discusses New Drug Development and AI Integration
07/09/2024 07:21 AM EDT NewMediaWire ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
07/02/2024 09:05 AM EDT NewMediaWire ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
06/25/2024 09:04 AM EDT NewMediaWire ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
Page